- On 26 February 2015, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product panitumumab (Vectibix). Read more here.
Thursday, 5 March 2015
European Medicines Agency recommends a variation to the terms of the marketing authorisation for panitumumab
The change concerns first-line combination treatment with FOLIFIRI.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment